MF 101

Drug Profile

MF 101

Alternative Names: Menerba; Menopause Formula 101; MF-101

Latest Information Update: 27 May 2015

Price : $50

At a glance

  • Originator Bionovo
  • Class Flavanones
  • Mechanism of Action Selective estrogen receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Vasomotor symptoms

Most Recent Events

  • 03 Apr 2012 Bionovo voluntarily suspends further enrolment in the phase III HERBA trial for Menopausal vasomotor symptoms in USA
  • 26 Oct 2011 Phase-III clinical trials in Menopausal vasomotor symptoms in USA (PO)
  • 30 Aug 2011 Adverse events data from a phase I trial in Vasomotor symptoms released by Bionovo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top